Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 27, 2011, Pages 11169-11174

  Seubert, Anja ^a   Calabro, Samuele ^a   Santini, Laura ^a   Galli, Barbara ^a   Genovese, Alessia ^a   Valentini, Sara ^a   Aprea, Susanna ^a   Colaprico, Annalisa ^a   D'Oro, Ugo ^a   Giuliani, Marzia M ^a   Pallaoro, Michele ^a   Pizza, Mariagrazia ^a   O'Hagan, Derek T ^a,b   Wack, Andreas ^a,c   Rappuoli, Rino ^a   De Gregorio, Ennio ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; FREUND ADJUVANT; MIFAMURTIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BLOOD GROUP TYPING; EMULSION; FEMALE; IN VITRO STUDY; MALE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CARRIER PROTEINS; EMULSIONS; FEMALE; FREUND'S ADJUVANT; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEISSERIA MENINGITIDIS, SEROGROUP B; POLYSORBATES; SIGNAL TRANSDUCTION; SQUALENE; TOLL-LIKE RECEPTORS; VACCINES, SYNTHETIC;

MUS; NEISSERIA MENINGITIDIS;

EID: 79960608092     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107941108     Document Type: Article

References (30)

1. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783-801. (Pubitemid 43261452)
2. Adachi O, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9(1):143-150. (Pubitemid 28361303)
3. He B, et al. (2010) The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 11:836-845.
4. Nemazee D, Gavin A, Hoebe K, Beutler B (2006) Immunology: Toll-like receptors and antibody responses. Nature 441(7091):E4. (Pubitemid 44050162)
5. Morefield GL, et al. (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23:1588-1595. (Pubitemid 40203396)
6. Rimaniol AC, et al. (2004) Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22:3127-3135.
7. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A (2008) The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180:5402-5412.
8. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA (2001) The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69:1151-1159. (Pubitemid 32109584)
9. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122-1126. (Pubitemid 351871731)
10. Li H, Nookala S, Re F (2007) Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178:5271-5276. (Pubitemid 46595312)
11. Li H, Willingham SB, Ting JP, Re F (2008) Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181(1):17-21.
12. Kool M, et al. (2008) Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181:3755-3759.
13. McKee AS, et al. (2009) Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183:4403-4414.
14. Franchi L, Núñez G (2008) The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38:2085-2089.
15. Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 19:2673-2680.
16. Clark TW, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361:2424-2435.
17. Banzhoff A, et al. (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4:e4384.
18. Dupuis M, et al. (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186(1):18-27. (Pubitemid 28285344)
19. Mosca F, et al. (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105:10501-10506.
20. Calabro S, et al. (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29:1812-1823.
21. Gavin AL, et al. (2006) Adjuvant-enhanced antibody responses in the absence of tolllike receptor signaling. Science 314:1936-1938. (Pubitemid 46026117)
22. Giuliani MM, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103:10834-10839. (Pubitemid 44148381)
23. Donnelly J, et al. (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 107:19490-19495.
24. Hornung V, et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847-856.
25. Ellebedy AH, et al. (2011) Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc Natl Acad Sci USA 108:2927-2932.
26. Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: Guardians of the body. Annu Rev Immunol 27:229-265.
27. Abi Abdallah DS, Egan CE, Butcher BA, Denkers EY (2011) Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol 23:317-326.
28. Comanducci M, et al. (2002) NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195:1445-1454. (Pubitemid 34602821)
29. Pizza M, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820.
30. Borrow R, et al. (2005) Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 12:970-976.